181 related articles for article (PubMed ID: 22800836)
1. From pro-prostate specific antigen, [-2]pro-prostate specific antigen to Beckman Coulter phi: the evolution of new biomarkers for early detection of prostatic carcinoma.
Zhang MZ; Lu YP
Chin Med J (Engl); 2012 May; 125(9):1643-9. PubMed ID: 22800836
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
[TBL] [Abstract][Full Text] [Related]
3. [Use of [-2] pro PSA and phi index for early detection of prostate cancer: a prospective of 452 patients].
Houlgatte A; Vincendeau S; Desfemmes F; Ramirez J; Benoist N; Bensalah K; Durand X
Prog Urol; 2012 May; 22(5):279-83. PubMed ID: 22515924
[TBL] [Abstract][Full Text] [Related]
4. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
Mikolajczyk SD; Rittenhouse HG
Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
7. PSA Isoforms' Velocities for Early Diagnosis of Prostate Cancer.
Heidegger I; Klocker H; Pichler R; Horninger W; Bektic J
Anticancer Res; 2015 Jun; 35(6):3567-70. PubMed ID: 26026127
[TBL] [Abstract][Full Text] [Related]
8. Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.
Stephan C; Meyer HA; Paul EM; Kristiansen G; Loening SA; Lein M; Jung K
Anticancer Res; 2007; 27(4A):1833-6. PubMed ID: 17649780
[TBL] [Abstract][Full Text] [Related]
9. [Recent advances in proPSA on early detection in prostate cancer].
Zhu PY; Hong P; Huang YF
Zhonghua Nan Ke Xue; 2005 Dec; 11(12):944-6. PubMed ID: 16398372
[TBL] [Abstract][Full Text] [Related]
10. PSA and other tissue kallikreins for prostate cancer detection.
Stephan C; Jung K; Lein M; Diamandis EP
Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069
[TBL] [Abstract][Full Text] [Related]
11. [New biomarkers and application of multivariate models for detection of prostate cancer].
Stephan C; Cammann H; Rittenhouse H; Lein M; Jentzmik F; Schrader M; Deger S; Miller K; Jung K
Aktuelle Urol; 2009 Aug; 40(4):221-30. PubMed ID: 19634072
[TBL] [Abstract][Full Text] [Related]
12. A (-5, -7) proPSA based artificial neural network to detect prostate cancer.
Stephan C; Meyer HA; Kwiatkowski M; Recker F; Cammann H; Loening SA; Jung K; Lein M
Eur Urol; 2006 Nov; 50(5):1014-20. PubMed ID: 16697520
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer.
Parwani AV; Marlow C; Demarzo AM; Mikolajczyk SD; Rittenhouse HG; Veltri RW; Chan TY
Am J Surg Pathol; 2006 Oct; 30(10):1231-6. PubMed ID: 17001152
[TBL] [Abstract][Full Text] [Related]
14. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer.
Mikolajczyk SD; Marker KM; Millar LS; Kumar A; Saedi MS; Payne JK; Evans CL; Gasior CL; Linton HJ; Carpenter P; Rittenhouse HG
Cancer Res; 2001 Sep; 61(18):6958-63. PubMed ID: 11559576
[TBL] [Abstract][Full Text] [Related]
15. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.
Lein M; Semjonow A; Graefen M; Kwiatkowski M; Abramjuk C; Stephan C; Haese A; Chun F; Schnorr D; Loening SA; Jung K
J Urol; 2005 Dec; 174(6):2150-3. PubMed ID: 16280753
[TBL] [Abstract][Full Text] [Related]
16. Pro PSA : a "pro cancer" form of PSA?
Peyromaure M; Fulla Y; Debré B; Dinh-Xuan AT
Med Hypotheses; 2005; 64(1):92-5. PubMed ID: 15533620
[TBL] [Abstract][Full Text] [Related]
17. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer.
Hori S; Blanchet JS; McLoughlin J
BJU Int; 2013 Oct; 112(6):717-28. PubMed ID: 22759214
[TBL] [Abstract][Full Text] [Related]
18. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.
Mikolajczyk SD; Millar LS; Wang TJ; Rittenhouse HG; Marks LS; Song W; Wheeler TM; Slawin KM
Cancer Res; 2000 Feb; 60(3):756-9. PubMed ID: 10676664
[TBL] [Abstract][Full Text] [Related]
19. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer.
de Vries SH; Raaijmakers R; Blijenberg BG; Mikolajczyk SD; Rittenhouse HG; Schröder FH
Urology; 2005 May; 65(5):926-30. PubMed ID: 15882725
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of (-2)proPSA in combination with total PSA and free PSA for the early detection of prostate cancer].
Lamy PJ; Montels F; Tosi D; Leizour B; Bascoul-Mollevi C; Castan F; Roques S; Nielloud F; Rebillard X
Ann Biol Clin (Paris); 2013; 71(5):537-44. PubMed ID: 24113439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
